Business
Medicus Pharma Ltd. to Present at Biotech Showcase 2026 as SkinJect Phase 2 Clinical Data Approaches Readout and Partnering Readiness Accelerates
The Company enters 2026 with Multiple Phase 2 Catalysts collectively representing ~$8 billion in potential market opportunities, an AI-enabled development strategy, and regulatory optionalityPHILADELPHIA, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company"), a precision guided biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutics assets, is pleased to announce that it will
About this update from Medicus Pharma Ltd.
[{"type":"image","alt":"Medicus Pharma Ltd","displaySize":"","headline":null,"caption":"Medicus Pharma Ltd","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":105,"url":"https://media.zenfs.com/en/globenewswire.com/536b378d21fd9e670e64143c1efe36b1"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/nCO_2.f05f6STHaWB5vZCg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE0NztjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/536b378d21fd9e670e64143c1efe36b1","width":300,"height":105}},"lazy":false},{"type":"text","content":"The Company enters 2026 with Multiple Phase 2 Catalysts collectively representing ~$8 billion in potential market opportunities, an AI-enabled development strategy, and regulatory optionality","length":191,"tagName":"p"},{"type":"text","content":"PHILADELPHIA, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company"), a precision guided biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutics assets, is pleased to announce that it will present at Biotech Showcase 2026, taking place January 12–14, 2026, in San Francisco.","length":415,"tagName":"p"},{"type":"text","content":"Dr. Raza Bokhari, Executive Chairman & CEO of Medicus will deliver a company presentation as Medicus enters 2026 with multiple Phase 2 Catalysts across clinical, regulatory, and pipeline expansion programs.","length":210,"tagName":"p"},{"type":"text","content":"Biotech Showcase Presentation Details","length":37,"tagName":"p"},{"type":"table","headerItems":[],"items":[{"val":[{"style":"text-align:justify;vertical-align:middle;vertical-align:top;","val":[{"type":"text","content":"Presentation Date:","length":18,"tagName":"p","attribs":{}}]},{"style":"text-align:justify;vertical-align:middle;vertical-align:top;","val":[{"type":"text","content":"Tuesday, January 13, 2026","length":25,"tagName":"p","attribs":{}}]}]},{"val":[{"style":"text-align:justify;vertical-align:middle;vertical-align:top;","val":[{"type":"text","content":"Time:","length":5,"tagName":"p","attribs":{}}]},{"style":"text-align:justify;vertical-align:middle;vertical-align:top;","val":[{"type":"text","content":"10:00 a.m. Pacific time","length":23,"tagName":"p","attribs":{}}]}]},{"val":[{"style":"text-align:justify;vertical-align:middle;verti...